{"id":4685,"date":"2024-10-22T10:02:28","date_gmt":"2024-10-22T00:02:28","guid":{"rendered":"\/eu-uk\/?p=4685"},"modified":"2024-10-22T10:02:28","modified_gmt":"2024-10-22T00:02:28","slug":"meet-the-board-chairman-john-van-der-wielen","status":"publish","type":"post","link":"\/eu-uk\/blog\/2024\/10\/22\/meet-the-board-chairman-john-van-der-wielen\/","title":{"rendered":"Meet The Board | Chairman, John Van Der Wielen"},"content":{"rendered":"

The third episode of Orthocell\u2019s \u2018Meet the Board\u2019 video series is now online – featuring Chairman, John Van Der Wielen.<\/p>\n

Drawing on over 30 years\u2019 experience in executive leadership roles, John shares his vision for Orthocell’s groundbreaking nerve repair technology and its potential to transform patient outcomes while reducing healthcare costs, particularly as the Company expands into the significant US market.<\/p>\n

Here\u2019s an excerpt:<\/p>\n

\u201cWe’re at the phase where the Company will take off. At this stage, investors are getting into something with a relatively low market cap, an extremely strong Board, and we’re about to enter the US market. It’s a compelling investment for anyone who wishes to get into the medical device business, and there aren’t many listed Australian medical companies that have this potential.”<\/em><\/p>\n